TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia
Brief Summary: The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.


Options:
A: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4 mg Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 4 mg Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 160 mg LY2140023, 80 mg LY2140023
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: New Physiopathogenics Mechanisms Susceptible of Pharmacological Developments (Insulin Resistance and Atherosclerosis)
Brief Summary: The study aims to evaluate IFG, IGT or unknown type 2 diabetes mellitus in new classes at high risk to develop alterations of glucose metabolism and definition of new pathogenic mechanisms of insulin resistance and atherosclerosis.

The following classes of subjects at high risk will be considered:First degree relatives of patients with type 2 diabetes mellitus, patients with cardiovascular disease and stroke, patients with heart valve disease. age will be \> 30 years, both gender.


Options:
A: Arm Label: Lifestyle intervention (nutrition); Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention (nutrition) | Arm Label: Lifestyle counseling (physical activity); Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention (physical activity) | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention (nutrition); Assigned to Arm(s): Lifestyle intervention (nutrition) | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention (physical activity); Assigned to Arm(s): Lifestyle counseling (physical activity)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
C: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
D: Arm Label: 1,2,3; Type: N/A; Interventions: N/A | Arm Label: 4; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Blood Pressure in Colorado
Brief Summary: We will improve hypertension control in Colorado by implementing a population-based intervention using interactive voice response (IVR) technology that will be delivered to patients in three healthcare systems across Colorado (Denver Health and Hospitals \[DH\], VA Colorado Healthcare System \[VA\], and Kaiser Permanente of Colorado \[KPCO\]). Together, these organizations serve over 1 million Coloradans. The IVR-based hypertension program will: 1) reach out to more patients using fewer resources than a traditional patient visit approach, 2) implement evidence based guidelines for therapy, 3) facilitate patients' acquisition of medications by allowing them to order and receive medications at home, and 4) enhance medication adherence using tailored educational and motivational messages.

HYPOTHESES:

1. A sizable population of patients is at high risk for further cardiovascular morbidity and mortality, based on uncontrolled hypertension.
2. An IVR-centered intervention among patients with diagnosed but uncontrolled hypertension is feasible.
3. An IVR-centered intervention plus usual care for these patients improves BP control, compared to usual care alone.


Options:
A: Arm Label: Reminder and Outreach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reminder and Outreach Intervention | Arm Label: Usual Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder and Outreach Intervention; Assigned to Arm(s): Reminder and Outreach Intervention
B: Arm Label: Technology-supported care; Type: EXPERIMENTAL; Interventions: Other: Technology-supported care | Arm Label: Supported-Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Technology-supported care; Assigned to Arm(s): Technology-supported care
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multi-component physical activity counseling program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multi-component physical activity counseling program; Assigned to Arm(s): Arm 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Use of telephone-based Interactive Voice Recognition system | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Use of telephone-based Interactive Voice Recognition system; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Brief Summary: Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with buprenorphine is associated shorter stays in the hospital and fewer days of treatment than the use of standard therapy. Another secondary goal will be to understand buprenorphine concentration in the blood of babies treated with the drug (this is called "pharmacokinetics").


Options:
A: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control
B: Arm Label: Song of Kin; Type: EXPERIMENTAL; Interventions: Behavioral: Song of Kin | Arm Label: Gato box; Type: EXPERIMENTAL; Interventions: Other: Gato box | Arm Label: Ocean disc; Type: EXPERIMENTAL; Interventions: Other: Ocean disc | Arm Label: Contingent singing; Type: EXPERIMENTAL; Interventions: Other: Contingent singing | Arm Label: Tonal Vocal holding; Type: EXPERIMENTAL; Interventions: Other: Tonal Vocal holding | Arm Label: Muted shaker; Type: EXPERIMENTAL; Interventions: Other: Muted shaker | Intervention Type: BEHAVIORAL; Name: Song of Kin; Assigned to Arm(s): Song of Kin | Intervention Type: OTHER; Name: Gato box; Assigned to Arm(s): Gato box | Intervention Type: OTHER; Name: Ocean disc; Assigned to Arm(s): Ocean disc | Intervention Type: OTHER; Name: Contingent singing; Assigned to Arm(s): Contingent singing | Intervention Type: OTHER; Name: Tonal Vocal holding; Assigned to Arm(s): Tonal Vocal holding | Intervention Type: OTHER; Name: Muted shaker; Assigned to Arm(s): Muted shaker
C: Arm Label: methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): morphine
D: Arm Label: Oral morphine solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral morphine solution | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine | Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oral morphine solution; Assigned to Arm(s): Oral morphine solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas
Brief Summary: The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in patients with acromegaly.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide Implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sandostatin LAR Depot | Intervention Type: DRUG; Name: Octreotide Implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sandostatin LAR Depot; Assigned to Arm(s): 2
B: Arm Label: octreotide; Type: EXPERIMENTAL; Interventions: Drug: Octreotide | Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Direct surgery for acromegaly | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): octreotide | Intervention Type: PROCEDURE; Name: Direct surgery for acromegaly; Assigned to Arm(s): standard surgery
C: Arm Label: CAM2029 10 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 10 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Intervention Type: DRUG; Name: octreotide FluidCrystal® injection depot; Assigned to Arm(s): CAM2029 10 mg (Acromegaly), CAM2029 10 mg (NET), CAM2029 20 mg (Acromegaly), CAM2029 20 mg (NET)
D: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide LAR | Intervention Type: DRUG; Name: Pasireotide LAR; Assigned to Arm(s): Pasireotide LAR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity as an Aid for Smoking Cessation: a Randomized Controlled Trial
Brief Summary: Including a tailored moderate-intensity physical activity intervention in a standard smoking cessation treatment program (pharmaceutical treatment and counseling) increases the chances of quitting and reduces nicotine withdrawal symptoms, negative moods, stress, and weight gain.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week risk reduction program, managed by a Heart Health Educator | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 12-week risk reduction program, managed by a Heart Health Educator; Assigned to Arm(s): 1
B: Arm Label: PA+ Smoking Cessation (LMPA); Type: EXPERIMENTAL; Interventions: Behavioral: PA+ Smoking Cessation (LMPA) | Arm Label: Standard Care Smoking Counseling (SCC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care Smoking Counseling (SCC) | Intervention Type: BEHAVIORAL; Name: PA+ Smoking Cessation (LMPA); Assigned to Arm(s): PA+ Smoking Cessation (LMPA) | Intervention Type: BEHAVIORAL; Name: Standard Care Smoking Counseling (SCC); Assigned to Arm(s): Standard Care Smoking Counseling (SCC)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Allez Hop | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Allez Hop; Assigned to Arm(s): A
D: Arm Label: CBT+ Contact; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT+ Contact | Arm Label: CBT+ Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT+ Exercise | Intervention Type: BEHAVIORAL; Name: CBT+ Contact; Assigned to Arm(s): CBT+ Contact | Intervention Type: BEHAVIORAL; Name: CBT+ Exercise; Assigned to Arm(s): CBT+ Exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity as an Aid for Smoking Cessation: a Randomized Controlled Trial
Brief Summary: Including a tailored moderate-intensity physical activity intervention in a standard smoking cessation treatment program (pharmaceutical treatment and counseling) increases the chances of quitting and reduces nicotine withdrawal symptoms, negative moods, stress, and weight gain.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Arm Label: physical activity program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Intervention Type: BEHAVIORAL; Name: Exercise and counseling (for smoking cessation and physical activity); Assigned to Arm(s): Control, physical activity program
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Allez Hop | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Allez Hop; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients
Brief Summary: A primary goal of this study is to investigate the significance of treatment duration, by comparing change after group psychotherapy of varying lengths. A secondary goal is to investigate the predictive value of selected patient variables on outcome: personality pathology, quality of object relations, presence of personality disorder, degree of initial disturbance, and education. One hundred and twenty patients from 5-6 different study sites (consisting of one coordinator and 3 therapists) will be included. Exclusion criteria are psychosis, substance abuse, and organically based symptoms. Patients are interviewed before treatment and one year after termination, and self-rated outcome measures are filled in at 3-month intervals during treatment and at termination. After an initial evaluation, patients are randomized to one of two manualized psychodynamic group psychotherapies with different treatment lengths (20 and 80 sessions). Each therapist will conduct both a short- and a long-term group, and sessions are taped in order to check treatment integrity.


Options:
A: Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention; Assigned to Arm(s): Teachable Moment Brief Intervention
B: Arm Label: short-term dynamic therapy; Type: EXPERIMENTAL; Interventions: Behavioral: short-term dynamic therapy | Arm Label: long-term dynamic therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: long-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: short-term dynamic therapy; Assigned to Arm(s): short-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: long-term dynamic therapy; Assigned to Arm(s): long-term dynamic therapy
C: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
D: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients
Brief Summary: A primary goal of this study is to investigate the significance of treatment duration, by comparing change after group psychotherapy of varying lengths. A secondary goal is to investigate the predictive value of selected patient variables on outcome: personality pathology, quality of object relations, presence of personality disorder, degree of initial disturbance, and education. One hundred and twenty patients from 5-6 different study sites (consisting of one coordinator and 3 therapists) will be included. Exclusion criteria are psychosis, substance abuse, and organically based symptoms. Patients are interviewed before treatment and one year after termination, and self-rated outcome measures are filled in at 3-month intervals during treatment and at termination. After an initial evaluation, patients are randomized to one of two manualized psychodynamic group psychotherapies with different treatment lengths (20 and 80 sessions). Each therapist will conduct both a short- and a long-term group, and sessions are taped in order to check treatment integrity.


Options:
A: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
B: Arm Label: short-term dynamic therapy; Type: EXPERIMENTAL; Interventions: Behavioral: short-term dynamic therapy | Arm Label: long-term dynamic therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: long-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: short-term dynamic therapy; Assigned to Arm(s): short-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: long-term dynamic therapy; Assigned to Arm(s): long-term dynamic therapy
C: Arm Label: Inpatient Adaptation of DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Inpatient Adaptation of DBT | Arm Label: Outpatient DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: standard outpatient DBT | Intervention Type: BEHAVIORAL; Name: standard outpatient DBT; Assigned to Arm(s): Outpatient DBT | Intervention Type: BEHAVIORAL; Name: Inpatient Adaptation of DBT; Assigned to Arm(s): Inpatient Adaptation of DBT
D: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control

Answer: B